Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05271461
Other study ID # COVID-19 LLLT.
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 1, 2022
Est. completion date June 4, 2022

Study information

Verified date February 2022
Source Cairo University
Contact Enas Dr Ahmed, BSC
Phone 01028406164
Email enaswagdydaib@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

COVID-19 clotting Safety


Description:

Covid-19 patients have liability for hyper coagulability, low level laser Therapy improve circulation and decrease liability for hyper coagulability accompanied with circulatory exercises .


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date June 4, 2022
Est. primary completion date April 4, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 35 Years to 45 Years
Eligibility Inclusion Criteria: - BMI from 18.5 to 29.9 kg/m2 - Moderate elevated percentage of coagulative factors for COVID-19 Diagnosis: - Nasopharyngeal swab - Sepsis induced coagulopathy score>4 - D_dimer=0,5mg/L - Fibrinogen>2,5gm/L - C_reactive protein=10mg/L - Lymphocyte count<1,500mm3 - Platelet count<150,000mm3 - Prothrombin time increase>3sec - Activated partial thromboplastin time increase>5sec - Same level of physical activity - Patients can swallow tablets - CT scan screening method for COVID-19 Diagnosis - Physical examination Exclusion Criteria: - hyper tension - Cognitive impairment e.g (delirium) - Diabetes mellitus both types dependant or non - Disabled musculoskeletal Disorders e.g hemi paresis - Coronary artery diseases and heart failure - DVT - Stroke, bone disease, renal failure, pulmonary embolism - Vitamins deficiency - 6 months post large surgeries - Alcohol intake and smokers - Thyroid diseases

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Low level laser Therapy
Pin pointed application of low level laser on 15 acupuncture points each point 1 min time of application 15 min.
Other:
Circulatory exercises
Active assisted or against mild resistance. Supine with leg up position 18degrees measured by the bed water balance in side rails. If patient is not comfortable according to the modified Borg scale or contra indicated for the position then assume the supine position. The subject will have A 3 min rest period to acclimatize themselves to each position. The ankle pumping exercises consisted of simple repetitions of dorsiflexion 1 sec and planter- flexion for 1 sec with three different exercise intervals: repeated dorsiflexion and planter-flexion with no rest (no rest exercise). repeated dorsiflexion and planter-flexion with a 2 sec rest period (2 sec rest exercise). repeated dorsiflexion and planter-flexion with 4sec rest period (4sec rest exercise). Subjects will have practiced ankle pumps before the exercise to get familiar and be educated about the procedure.

Locations

Country Name City State
Egypt Physical therapy faculty Dokki Giza

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

References & Publications (3)

Agaiby AD, Ghali LR, Wilson R, Dyson M. Laser modulation of angiogenic factor production by T-lymphocytes. Lasers Surg Med. 2000;26(4):357-63. — View Citation

ConnorsJ.M.,LevyJ.H(2020).Thromboinflammation and the hyper coagulability of COVID-19.JThromb Haemost https://doi.org/10.1111/jth.14849.

Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis. Arch Acad Emerg Med. 2020 Mar 24;8(1):e35. eCollection 2020. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Circulatory group laboratory investigation. D-dimer=.5mg/dL, fibrinogen>2.5mg/dL
To examine COVID-19 recovery.
Monthly (an average of two months)
Primary Circulatory group: CBC analysis. Lymphocyte count<1.500mm3, Platelet count<150.000mm3, to examine COVID-19 recovery. Daily (an average of two months)
Primary Circulatory group (PT, PTT). Prothrombin time>3 sec, activated partial thromboplastin time>5 sec to examine COVID-19 recovery. Bi weekly (an average of two months)
Primary Circulatory group physical examination. by visual analog scale is horizontal line 100mm length the ends defined as extreme limit of the parameter measured (symptom, pain, health) orientated from the left (the worst) the right (the best) 3 times per week to detect DVT. Every two days (an average of two months)
Primary Circulatory group. BMI. weight kg on height m2 to detect liability for DVT. Day one
Primary Especially Lab investigation. C-reactive protein =10mg/l for diagnosis of the recovery. Baseline
Secondary LLLT group laboratory investigation. D-dimer=,5mg/dl, fibrinogen>2.5mg/dl, c-reactive protein=10mg/dl to examine COVID-19 recovery.
Fibrinogen
Monthly (an average of two months)
Secondary LLLT group CBC analysis. lymphocyte count<1,500mm3, platelet count<150,000mm3, for examine COVID-19 recovery. Daily (an average of two months)
Secondary LLLT group. {PTT, PT}. Prothrombin time>3 sec, activated partial thromboplastin time>5sec to examine COVID-19 recovery. Bi weekly (an average of two months)
Secondary LLLT group physical examination. by visual analog scale is a straight horizontal line of fixed length 100mm the end is extreme limit of the parameter measured (symptom, pain, health) orientated from the left (the worst) to the right (the best) 3times per week to detect DVT. Every two days (an average of two months)
Secondary LLLT group. BMI. Weight kg/height m2 to detect liability for DVT. Day one
Secondary Specifically Lab investigation. C_reactive protein=10mg/l.help diagnosis of the recovery. Baseline
See also
  Status Clinical Trial Phase
Suspended NCT04901676 - Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia Phase 3
Not yet recruiting NCT04534478 - Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19 Phase 4
Active, not recruiting NCT05002517 - Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab Phase 3
Completed NCT05008393 - Efficacy of PJS-539 for Adult Patients With COVID-19. Phase 2
Completed NCT04569877 - GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia Phase 2
Not yet recruiting NCT05286255 - Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias Phase 1
Completed NCT05035589 - The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
Recruiting NCT06113432 - CPAP Therapy Through a Helmet or a Full Face Mask in Patients With Acute Hypoxemic Respiratory Failure: Cross-over Study N/A
Recruiting NCT05042063 - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Recruiting NCT04615429 - Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19 Phase 2
Completed NCT05047653 - RALE Versus CORADS/CT-Severity Score in COVID-19
Active, not recruiting NCT05047016 - Study to Evaluate the Dynamic Consent Model Based on the Blockchain-based Clinical Trial Platform METORY N/A
Active, not recruiting NCT05033847 - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above Phase 2
Recruiting NCT06113757 - Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease N/A
Completed NCT05504655 - N-Acetylcysteine as an Adjuvant Therapy in Critically Ill COVID-19 Patients:
Active, not recruiting NCT05035524 - A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19 N/A
Completed NCT05065879 - Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes Phase 4
Withdrawn NCT04390217 - LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia Phase 2
Withdrawn NCT04460105 - Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia Phase 1
Suspended NCT04901689 - Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation Phase 3